ID   ERCC5_HUMAN             Reviewed;        1186 AA.
AC   P28715; A6NGT4; Q5JUS4; Q5JUS5; Q7Z2V3; Q8IZL6; Q8N1B7; Q9HD59; Q9HD60;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 3.
DT   28-JUN-2023, entry version 237.
DE   RecName: Full=DNA excision repair protein ERCC-5 {ECO:0000305};
DE            EC=3.1.-.- {ECO:0000269|PubMed:32522879, ECO:0000269|PubMed:32821917, ECO:0000269|PubMed:7651464, ECO:0000269|PubMed:8078765, ECO:0000269|PubMed:8090225, ECO:0000269|PubMed:8206890};
DE   AltName: Full=DNA repair protein complementing XP-G cells;
DE   AltName: Full=Xeroderma pigmentosum group G-complementing protein;
GN   Name=ERCC5; Synonyms=ERCM2, XPG, XPGC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ARG-1053; ARG-1080 AND
RP   HIS-1104.
RX   PubMed=8483504; DOI=10.1038/363182a0;
RA   Scherly D., Nouspikel T., Corlet J., Ucla C., Bairoch A., Clarkson S.G.;
RT   "Complementation of the DNA repair defect in Xeroderma pigmentosum group G
RT   cells by a human cDNA related to yeast RAD2.";
RL   Nature 363:182-185(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS VAL-254; ARG-1053 AND
RP   ARG-1080.
RX   PubMed=7510366; DOI=10.1016/0921-8777(94)90080-9;
RA   Shiomi T., Harada Y.-N., Saito T., Shiomi N., Okuno Y., Yamaizumi M.;
RT   "An ERCC5 gene with homology to yeast RAD2 is involved in group G Xeroderma
RT   pigmentosum.";
RL   Mutat. Res. 314:167-175(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS VAL-254; ARG-1053 AND
RP   ARG-1080.
RX   PubMed=8413238; DOI=10.1128/mcb.13.10.6393-6402.1993;
RA   Macinnes M.A., Dickson J.A., Hernandez R.R., Learmonth D., Lin G.Y.,
RA   Mudgett J.S., Park M.S., Schauer S., Reynolds R.J., Strniste G.F., Yu J.Y.;
RT   "Human ERCC5 cDNA-cosmid complementation for excision repair and bipartite
RT   amino acid domains conserved with RAD proteins of Saccharomyces cerevisiae
RT   and Schizosaccharomyces pombe.";
RL   Mol. Cell. Biol. 13:6393-6402(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING (ISOFORMS 1 AND
RP   3).
RX   PubMed=11266544; DOI=10.1093/nar/29.7.1443;
RA   Emmert S., Schneider T.D., Khan S.G., Kraemer K.H.;
RT   "The human XPG gene: gene architecture, alternative splicing and single
RT   nucleotide polymorphisms.";
RL   Nucleic Acids Res. 29:1443-1452(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS VAL-254;
RP   ARG-1053 AND ARG-1080.
RC   TISSUE=Bone marrow;
RA   Zan Q., Guo J.H., Yu L.;
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-181; VAL-254; ARG-256;
RP   CYS-311; LYS-399; SER-529; ILE-590; LEU-597; SER-879; HIS-1009 AND
RP   ARG-1053; ARG-1080 AND GLN-1080.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS ARG-1053
RP   AND ARG-1080.
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-88.
RX   PubMed=8088806; DOI=10.1006/geno.1994.1261;
RA   Samec S., Jones T.A., Corlet J., Scherly D., Sheer D., Wood R.D.,
RA   Clarkson S.G.;
RT   "The human gene for Xeroderma pigmentosum complementation group G (XPG)
RT   maps to 13q33 by fluorescence in situ hybridization.";
RL   Genomics 21:283-285(1994).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8206890; DOI=10.1016/s0021-9258(17)33956-x;
RA   O'Donovan A., Scherly D., Clarkson S.G., Wood R.D.;
RT   "Isolation of active recombinant XPG protein, a human DNA repair
RT   endonuclease.";
RL   J. Biol. Chem. 269:15965-15968(1994).
RN   [11]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=8090225; DOI=10.1038/371432a0;
RA   O'Donovan A., Davies A.A., Moggs J.G., West S.C., Wood R.D.;
RT   "XPG endonuclease makes the 3' incision in human DNA nucleotide excision
RT   repair.";
RL   Nature 371:432-435(1994).
RN   [12]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=8078765; DOI=10.1093/nar/22.16.3312;
RA   Habraken Y., Sung P., Prakash L., Prakash S.;
RT   "Human Xeroderma pigmentosum group G gene encodes a DNA endonuclease.";
RL   Nucleic Acids Res. 22:3312-3316(1994).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=7651464; DOI=10.1016/0165-7992(95)90070-5;
RA   Cloud K.G., Shen B., Strniste G.F., Park M.S.;
RT   "XPG protein has a structure-specific endonuclease activity.";
RL   Mutat. Res. 347:55-60(1995).
RN   [14]
RP   INTERACTION WITH PCNA.
RX   PubMed=9305916; DOI=10.1074/jbc.272.39.24522;
RA   Gary R., Ludwig D.L., Cornelius H.L., MacInnes M.A., Park M.S.;
RT   "The DNA repair endonuclease XPG binds to proliferating cell nuclear
RT   antigen (PCNA) and shares sequence elements with the PCNA-binding regions
RT   of FEN-1 and cyclin-dependent kinase inhibitor p21.";
RL   J. Biol. Chem. 272:24522-24529(1997).
RN   [15]
RP   FUNCTION, AND INTERACTION WITH NTHL1.
RX   PubMed=9927729; DOI=10.1093/nar/27.4.979;
RA   Bessho T.;
RT   "Nucleotide excision repair 3' endonuclease XPG stimulates the activity of
RT   base excision repair enzyme thymine glycol DNA glycosylase.";
RL   Nucleic Acids Res. 27:979-983(1999).
RN   [16]
RP   REVIEW.
RX   PubMed=14726017; DOI=10.1016/j.biochi.2003.10.014;
RA   Clarkson S.G.;
RT   "The XPG story.";
RL   Biochimie 85:1113-1121(2003).
RN   [17]
RP   REVIEW ON VARIANTS XP-G.
RX   PubMed=10447254;
RX   DOI=10.1002/(sici)1098-1004(1999)14:1<9::aid-humu2>3.0.co;2-6;
RA   Cleaver J.E., Thompson L.H., Richardson A.S., States J.C.;
RT   "A summary of mutations in the UV-sensitive disorders: xeroderma
RT   pigmentosum, Cockayne syndrome, and trichothiodystrophy.";
RL   Hum. Mutat. 14:9-22(1999).
RN   [18]
RP   FUNCTION, INTERACTION WITH ERCC6 AND RNA POLYMERASE II, SUBCELLULAR
RP   LOCATION, AND DOMAIN.
RX   PubMed=16246722; DOI=10.1016/j.molcel.2005.09.022;
RA   Sarker A.H., Tsutakawa S.E., Kostek S., Ng C., Shin D.S., Peris M.,
RA   Campeau E., Tainer J.A., Nogales E., Cooper P.K.;
RT   "Recognition of RNA polymerase II and transcription bubbles by XPG, CSB,
RT   and TFIIH: insights for transcription-coupled repair and Cockayne
RT   Syndrome.";
RL   Mol. Cell 20:187-198(2005).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-8, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   FUNCTION, IDENTIFICATION IN THE HR COMPLEX, INTERACTION WITH BRCA1; BRCA2
RP   AND PALB2, SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=26833090; DOI=10.1016/j.molcel.2015.12.026;
RA   Trego K.S., Groesser T., Davalos A.R., Parplys A.C., Zhao W., Nelson M.R.,
RA   Hlaing A., Shih B., Rydberg B., Pluth J.M., Tsai M.S., Hoeijmakers J.H.J.,
RA   Sung P., Wiese C., Campisi J., Cooper P.K.;
RT   "Non-catalytic Roles for XPG with BRCA1 and BRCA2 in Homologous
RT   Recombination and Genome Stability.";
RL   Mol. Cell 61:535-546(2016).
RN   [22] {ECO:0007744|PDB:5EKF, ECO:0007744|PDB:5EKG}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 1054-1077 AND OF 1168-1186 IN
RP   COMPLEX WITH MOUSE KPNA2, AND NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=26812207; DOI=10.1016/j.jmb.2016.01.019;
RA   Barros A.C., Takeda A.A., Dreyer T.R., Velazquez-Campoy A., Kobe B.,
RA   Fontes M.R.;
RT   "Structural and Calorimetric Studies Demonstrate that Xeroderma Pigmentosum
RT   Type G (XPG) Can Be Imported to the Nucleus by a Classical Nuclear Import
RT   Pathway via a Monopartite NLS Sequence.";
RL   J. Mol. Biol. 428:2120-2131(2016).
RN   [23] {ECO:0007744|PDB:6TUR, ECO:0007744|PDB:6TUS, ECO:0007744|PDB:6TUW, ECO:0007744|PDB:6TUX}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1-747 AND 750-990; OF MUTANT
RP   ALA-812; OF APO FORM AND IN COMPLEX WITH DNA, FUNCTION, CATALYTIC ACTIVITY,
RP   DOMAIN, AND DNA BINDING.
RX   PubMed=32821917; DOI=10.1093/nar/gkaa688;
RA   Gonzalez-Corrochano R., Ruiz F.M., Taylor N.M.I., Huecas S., Drakulic S.,
RA   Spinola-Amilibia M., Fernandez-Tornero C.;
RT   "The crystal structure of human XPG, the xeroderma pigmentosum group G
RT   endonuclease, provides insight into nucleotide excision DNA repair.";
RL   Nucleic Acids Res. 48:9943-9958(2020).
RN   [24] {ECO:0007744|PDB:6VBH}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 766-987, FUNCTION, CATALYTIC
RP   ACTIVITY, SUBUNIT, DOMAIN, AND MUTAGENESIS OF 67-PHE--PHE-68;
RP   955-LEU-ASP-956; PHE-978 AND LEU-981.
RX   PubMed=32522879; DOI=10.1073/pnas.1921311117;
RA   Tsutakawa S.E., Sarker A.H., Ng C., Arvai A.S., Shin D.S., Shih B.,
RA   Jiang S., Thwin A.C., Tsai M.S., Willcox A., Her M.Z., Trego K.S.,
RA   Raetz A.G., Rosenberg D., Bacolla A., Hammel M., Griffith J.D.,
RA   Cooper P.K., Tainer J.A.;
RT   "Human XPG nuclease structure, assembly, and activities with insights for
RT   neurodegeneration and cancer from pathogenic mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:14127-14138(2020).
RN   [25]
RP   INVOLVEMENT IN COFS3.
RX   PubMed=24700531; DOI=10.1002/ajmg.a.36506;
RA   Drury S., Boustred C., Tekman M., Stanescu H., Kleta R., Lench N.,
RA   Chitty L.S., Scott R.H.;
RT   "A novel homozygous ERCC5 truncating mutation in a family with prenatal
RT   arthrogryposis--further evidence of genotype-phenotype correlation.";
RL   Am. J. Med. Genet. A 164A:1777-1783(2014).
RN   [26]
RP   VARIANT XP-G VAL-792.
RX   PubMed=7951246; DOI=10.1093/hmg/3.6.963;
RA   Nouspikel T., Clarkson S.G.;
RT   "Mutations that disable the DNA repair gene XPG in a Xeroderma pigmentosum
RT   group G patient.";
RL   Hum. Mol. Genet. 3:963-967(1994).
RN   [27]
RP   RETRACTED PAPER.
RX   PubMed=9096355; DOI=10.1073/pnas.94.7.3116;
RA   Nouspikel T., Lalle P., Leadon S.A., Cooper P.K., Clarkson S.G.;
RT   "A common mutational pattern in Cockayne syndrome patients from Xeroderma
RT   pigmentosum group G: implications for a second XPG function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:3116-3121(1997).
RN   [28]
RP   RETRACTION NOTICE OF PUBMED:9096355.
RX   PubMed=17179216; DOI=10.1073/pnas.0609759103;
RA   Nouspikel T., Lalle P., Leadon S.A., Cooper P.K., Clarkson S.G.;
RL   Proc. Natl. Acad. Sci. U.S.A. 103:19606-19606(2006).
RN   [29]
RP   VARIANT XP-G HIS-72.
RX   PubMed=11228268; DOI=10.1203/00006450-200103000-00016;
RA   Zafeiriou D.I., Thorel F., Andreou A., Kleijer W.J., Raams A.,
RA   Garritsen V.H., Gombakis N., Jaspers N.G.J., Clarkson S.G.;
RT   "Xeroderma pigmentosum group G with severe neurological involvement and
RT   features of Cockayne syndrome in infancy.";
RL   Pediatr. Res. 49:407-412(2001).
RN   [30]
RP   VARIANT XP-G PRO-858.
RX   PubMed=11841555; DOI=10.1046/j.0022-202x.2001.01673.x;
RA   Lalle P., Nouspikel T., Constantinou A., Thorel F., Clarkson S.G.;
RT   "The founding members of xeroderma pigmentosum group G produce XPG protein
RT   with severely impaired endonuclease activity.";
RL   J. Invest. Dermatol. 118:344-351(2002).
RN   [31]
RP   VARIANT XP-G THR-874.
RX   PubMed=12060391; DOI=10.1046/j.1523-1747.2002.01782.x;
RA   Emmert S., Slor H., Busch D.B., Batko S., Albert R.B., Coleman D.,
RA   Khan S.G., Abu-Libdeh B., DiGiovanna J.J., Cunningham B.B., Lee M.M.,
RA   Crollick J., Inui H., Ueda T., Hedayati M., Grossman L., Shahlavi T.,
RA   Cleaver J.E., Kraemer K.H.;
RT   "Relationship of neurologic degeneration to genotype in three xeroderma
RT   pigmentosum group G patients.";
RL   J. Invest. Dermatol. 118:972-982(2002).
RN   [32]
RP   VARIANTS XP-G ASP-28 AND CYS-968, AND CHARACTERIZATION OF VARIANTS XP-G
RP   ASP-28 AND CYS-968.
RX   PubMed=23255472; DOI=10.1002/humu.22259;
RA   Soltys D.T., Rocha C.R., Lerner L.K., de Souza T.A., Munford V., Cabral F.,
RA   Nardo T., Stefanini M., Sarasin A., Cabral-Neto J.B., Menck C.F.;
RT   "Novel XPG (ERCC5) mutations affect DNA repair and cell survival after
RT   ultraviolet but not oxidative stress.";
RL   Hum. Mutat. 34:481-489(2013).
RN   [33]
RP   VARIANT ALA-1078.
RX   PubMed=30533531; DOI=10.1212/nxg.0000000000000285;
RA   Reinthaler E.M., Graf E., Zrzavy T., Wieland T., Hotzy C., Kopecky C.,
RA   Pferschy S., Schmied C., Leutmezer F., Keilani M., Lill C.M., Hoffjan S.,
RA   Epplen J.T., Zettl U.K., Hecker M., Deutschlaender A., Meuth S.G.,
RA   Ahram M., Mustafa B., El-Khateeb M., Vilarino-Gueell C., Sadovnick A.D.,
RA   Zimprich F., Tomkinson B., Strom T., Kristoferitsch W., Lassmann H.,
RA   Zimprich A.;
RT   "TPP2 mutation associated with sterile brain inflammation mimicking MS.";
RL   Neurol. Genet. 4:e285-e285(2018).
CC   -!- FUNCTION: Single-stranded structure-specific DNA endonuclease involved
CC       in DNA excision repair (PubMed:8206890, PubMed:8090225, PubMed:8078765,
CC       PubMed:7651464, PubMed:32821917, PubMed:32522879). Makes the 3'incision
CC       in DNA nucleotide excision repair (NER) (PubMed:8090225,
CC       PubMed:8078765, PubMed:32821917, PubMed:32522879). Binds and bends DNA
CC       repair bubble substrate and breaks base stacking at the single-
CC       strand/double-strand DNA junction of the DNA bubble (PubMed:32522879).
CC       Plays a role in base excision repair (BER) by promoting the binding of
CC       DNA glycosylase NTHL1 to its substrate and increasing NTHL1 catalytic
CC       activity that removes oxidized pyrimidines from DNA (PubMed:9927729).
CC       Involved in transcription-coupled nucleotide excision repair (TCR)
CC       which allows RNA polymerase II-blocking lesions to be rapidly removed
CC       from the transcribed strand of active genes (PubMed:16246722).
CC       Functions during the initial step of TCR in cooperation with ERCC6/CSB
CC       to recognized stalled RNA polymerase II (PubMed:16246722). Also,
CC       stimulates ERCC6/CSB binding to the DNA repair bubble and ERCC6/CSB
CC       ATPase activity (PubMed:16246722). Required for DNA replication fork
CC       maintenance and preservation of genomic stability (PubMed:26833090,
CC       PubMed:32522879). Involved in homologous recombination repair (HRR)
CC       induced by DNA replication stress by recruiting RAD51, BRCA2, and PALB2
CC       to the damaged DNA site (PubMed:26833090). During HRR, binds to the
CC       replication fork with high specificity and stabilizes it
CC       (PubMed:32522879). Also, acts upstream of HRR, to promote the release
CC       of BRCA1 from DNA (PubMed:26833090). {ECO:0000269|PubMed:16246722,
CC       ECO:0000269|PubMed:26833090, ECO:0000269|PubMed:32522879,
CC       ECO:0000269|PubMed:32821917, ECO:0000269|PubMed:7651464,
CC       ECO:0000269|PubMed:8078765, ECO:0000269|PubMed:8090225,
CC       ECO:0000269|PubMed:8206890, ECO:0000269|PubMed:9927729}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:8206890};
CC       Note=Binds 2 magnesium ions per subunit. They probably participate in
CC       the reaction catalyzed by the enzyme. May bind an additional third
CC       magnesium ion after substrate binding. {ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 6.5-7. {ECO:0000269|PubMed:8206890};
CC   -!- SUBUNIT: Monomer (PubMed:32522879). Homodimer (PubMed:32522879).
CC       Component of the homologous recombination repair (HR) complex composed
CC       of ERCC5/XPG, BRCA2, PALB2, DSS1 and RAD51 (PubMed:26833090). Within
CC       the complex, interacts with BRCA2 and PALB2 (PubMed:26833090).
CC       Interacts with RNA polymerase II (PubMed:16246722). Interacts (via C-
CC       terminus) with ERCC6/CSB; the interaction stimulates ERCC6/CSB binding
CC       to the DNA repair bubble and ERCC6/CSB ATPase activity
CC       (PubMed:16246722). May form a complex composed of RNA polymerase II,
CC       ERCC6/CSB and ERCC5/XPG which associates with the DNA repair bubble
CC       during transcription-coupled nucleotide excision repair
CC       (PubMed:16246722). Interacts with BRCA1; the interaction promotes the
CC       release of BRCA1 from DNA (PubMed:26833090). Interacts with PCNA
CC       (PubMed:9305916). Interacts with NTHL1; the interaction stimulates
CC       NTHL1 activity and NTHL1 binding to its DNA substrate (PubMed:9927729).
CC       {ECO:0000269|PubMed:16246722, ECO:0000269|PubMed:26833090,
CC       ECO:0000269|PubMed:32522879, ECO:0000269|PubMed:9305916,
CC       ECO:0000269|PubMed:9927729}.
CC   -!- INTERACTION:
CC       P28715; P24522: GADD45A; NbExp=2; IntAct=EBI-765885, EBI-448167;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:16246722,
CC       ECO:0000269|PubMed:26833090, ECO:0000269|PubMed:7651464}. Chromosome
CC       {ECO:0000269|PubMed:26833090}. Note=Colocalizes with RAD51 to nuclear
CC       foci in S phase (PubMed:26833090). Localizes to DNA double-strand
CC       breaks (DBS) during replication stress (PubMed:26833090). Colocalizes
CC       with BRCA2 to nuclear foci following DNA replication stress
CC       (PubMed:26833090). {ECO:0000269|PubMed:26833090}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P28715-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28715-2; Sequence=VSP_035380;
CC       Name=3;
CC         IsoId=P28715-3; Sequence=VSP_053828, VSP_053829;
CC   -!- INDUCTION: Induced by replication stress caused by DNA double-strand
CC       breaks (DBS). {ECO:0000269|PubMed:26833090}.
CC   -!- DOMAIN: Both nuclear localization signals 1 and 2 act as a monopartite
CC       signal which binds to the high affinity site on KPNA2/importin-alpha.
CC       {ECO:0000269|PubMed:26812207}.
CC   -!- DOMAIN: Both the spacer region (also known as the recognition (R)
CC       domain) and C-terminal domain are required for stable binding to the
CC       DNA repair bubble (PubMed:16246722). However, both domains are
CC       dispensable for incision of DNA bubble structures (PubMed:16246722,
CC       PubMed:32821917, PubMed:32522879). {ECO:0000269|PubMed:16246722,
CC       ECO:0000269|PubMed:32522879, ECO:0000269|PubMed:32821917}.
CC   -!- DISEASE: Xeroderma pigmentosum complementation group G (XP-G)
CC       [MIM:278780]: An autosomal recessive pigmentary skin disorder
CC       characterized by solar hypersensitivity of the skin, high
CC       predisposition for developing cancers on areas exposed to sunlight and,
CC       in some cases, neurological abnormalities. The skin develops marked
CC       freckling and other pigmentation abnormalities. Some XP-G patients
CC       present features of Cockayne syndrome, cachectic dwarfism, pigmentary
CC       retinopathy, ataxia, decreased nerve conduction velocities. The
CC       phenotype combining xeroderma pigmentosum and Cockayne syndrome traits
CC       is referred to as XP-CS complex. {ECO:0000269|PubMed:10447254,
CC       ECO:0000269|PubMed:11228268, ECO:0000269|PubMed:11841555,
CC       ECO:0000269|PubMed:12060391, ECO:0000269|PubMed:23255472,
CC       ECO:0000269|PubMed:7951246}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Cerebro-oculo-facio-skeletal syndrome 3 (COFS3) [MIM:616570]:
CC       A disorder of prenatal onset characterized by microcephaly, congenital
CC       cataracts, facial dysmorphism, neurogenic arthrogryposis, growth
CC       failure and severe psychomotor retardation. COFS is considered to be
CC       part of the nucleotide-excision repair disorders spectrum that include
CC       also xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome.
CC       {ECO:0000269|PubMed:24700531}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: Includes a cryptic exon found in intron 6.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the XPG/RAD2 endonuclease family. XPG subfamily.
CC       {ECO:0000305}.
CC   -!- CAUTION: A paper describing an additional role for this protein in a
CC       base excision repair pathway that is not coupled to transcription has
CC       been retracted, because some of the experimental data were incorrect.
CC       {ECO:0000269|PubMed:9096355, ECO:0000305|PubMed:17179216}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/300/XPG";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ercc5/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X69978; CAA49598.1; -; mRNA.
DR   EMBL; D16305; BAA03812.1; -; mRNA.
DR   EMBL; L20046; AAC37533.1; -; mRNA.
DR   EMBL; AF255436; AAF89178.1; -; Genomic_DNA.
DR   EMBL; AF255431; AAF89178.1; JOINED; Genomic_DNA.
DR   EMBL; AF255433; AAF89178.1; JOINED; Genomic_DNA.
DR   EMBL; AF255434; AAF89178.1; JOINED; Genomic_DNA.
DR   EMBL; AF255435; AAF89178.1; JOINED; Genomic_DNA.
DR   EMBL; AF255442; AAF89179.1; -; Genomic_DNA.
DR   EMBL; AF255431; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255433; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255434; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255435; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255436; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255437; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255438; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255439; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255440; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF255441; AAF89179.1; JOINED; Genomic_DNA.
DR   EMBL; AF462447; AAP97715.1; -; mRNA.
DR   EMBL; AF550128; AAN46091.1; -; Genomic_DNA.
DR   EMBL; AL157769; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC031522; AAH31522.1; -; mRNA.
DR   EMBL; X71341; CAA50481.1; -; Genomic_DNA.
DR   EMBL; X71342; CAA50481.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS32004.1; -. [P28715-1]
DR   PIR; I58009; I58009.
DR   PIR; S35993; S35993.
DR   RefSeq; NP_000114.2; NM_000123.3. [P28715-1]
DR   PDB; 5EKF; X-ray; 2.00 A; B/C=1054-1077.
DR   PDB; 5EKG; X-ray; 2.80 A; B/C=1168-1186.
DR   PDB; 6TUR; X-ray; 2.90 A; AAA/BBB/CCC/DDD=1-747, AAA/BBB/CCC/DDD=750-990.
DR   PDB; 6TUS; X-ray; 2.50 A; A/B=1-747, A/B=750-990.
DR   PDB; 6TUW; X-ray; 3.50 A; A=1-747, A=750-990.
DR   PDB; 6TUX; X-ray; 3.10 A; A/B=1-747, A/B=750-986.
DR   PDB; 6VBH; X-ray; 2.00 A; A=766-987.
DR   PDBsum; 5EKF; -.
DR   PDBsum; 5EKG; -.
DR   PDBsum; 6TUR; -.
DR   PDBsum; 6TUS; -.
DR   PDBsum; 6TUW; -.
DR   PDBsum; 6TUX; -.
DR   PDBsum; 6VBH; -.
DR   AlphaFoldDB; P28715; -.
DR   SMR; P28715; -.
DR   BioGRID; 108385; 53.
DR   DIP; DIP-750N; -.
DR   ELM; P28715; -.
DR   IntAct; P28715; 14.
DR   STRING; 9606.ENSP00000347978; -.
DR   BindingDB; P28715; -.
DR   ChEMBL; CHEMBL4736; -.
DR   GlyCosmos; P28715; 2 sites, 1 glycan.
DR   GlyGen; P28715; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; P28715; -.
DR   PhosphoSitePlus; P28715; -.
DR   BioMuta; ERCC5; -.
DR   DMDM; 205371791; -.
DR   EPD; P28715; -.
DR   jPOST; P28715; -.
DR   MassIVE; P28715; -.
DR   MaxQB; P28715; -.
DR   PaxDb; P28715; -.
DR   PeptideAtlas; P28715; -.
DR   ProteomicsDB; 54495; -. [P28715-1]
DR   ProteomicsDB; 54496; -. [P28715-2]
DR   ProteomicsDB; 81837; -.
DR   Antibodypedia; 11224; 406 antibodies from 30 providers.
DR   DNASU; 2073; -.
DR   Ensembl; ENST00000652225.2; ENSP00000498881.2; ENSG00000134899.24. [P28715-1]
DR   GeneID; 2073; -.
DR   KEGG; hsa:2073; -.
DR   MANE-Select; ENST00000652225.2; ENSP00000498881.2; NM_000123.4; NP_000114.3.
DR   UCSC; uc001vpw.4; human. [P28715-1]
DR   AGR; HGNC:3437; -.
DR   CTD; 2073; -.
DR   DisGeNET; 2073; -.
DR   GeneCards; ERCC5; -.
DR   GeneReviews; ERCC5; -.
DR   HGNC; HGNC:3437; ERCC5.
DR   HPA; ENSG00000134899; Low tissue specificity.
DR   MalaCards; ERCC5; -.
DR   MIM; 133530; gene.
DR   MIM; 278780; phenotype.
DR   MIM; 616570; phenotype.
DR   neXtProt; NX_P28715; -.
DR   OpenTargets; ENSG00000134899; -.
DR   Orphanet; 1466; COFS syndrome.
DR   Orphanet; 910; Xeroderma pigmentosum.
DR   Orphanet; 220295; Xeroderma pigmentosum-Cockayne syndrome complex.
DR   PharmGKB; PA27851; -.
DR   VEuPathDB; HostDB:ENSG00000134899; -.
DR   eggNOG; KOG2520; Eukaryota.
DR   GeneTree; ENSGT00510000048601; -.
DR   HOGENOM; CLU_003018_2_0_1; -.
DR   InParanoid; P28715; -.
DR   OMA; CAEDARM; -.
DR   OrthoDB; 26655at2759; -.
DR   PhylomeDB; P28715; -.
DR   TreeFam; TF101235; -.
DR   PathwayCommons; P28715; -.
DR   Reactome; R-HSA-5696395; Formation of Incision Complex in GG-NER.
DR   Reactome; R-HSA-5696400; Dual Incision in GG-NER.
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   SignaLink; P28715; -.
DR   SIGNOR; P28715; -.
DR   BioGRID-ORCS; 2073; 25 hits in 1163 CRISPR screens.
DR   GeneWiki; ERCC5; -.
DR   GenomeRNAi; 2073; -.
DR   Pharos; P28715; Tchem.
DR   PRO; PR:P28715; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P28715; protein.
DR   Bgee; ENSG00000134899; Expressed in granulocyte and 97 other tissues.
DR   ExpressionAtlas; P28715; baseline and differential.
DR   Genevisible; P28715; HS.
DR   GO; GO:0005694; C:chromosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0000109; C:nucleotide-excision repair complex; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0000405; F:bubble DNA binding; IDA:UniProtKB.
DR   GO; GO:0003684; F:damaged DNA binding; IDA:UniProtKB.
DR   GO; GO:0004520; F:DNA endonuclease activity; IDA:UniProtKB.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0004519; F:endonuclease activity; IDA:UniProtKB.
DR   GO; GO:0008047; F:enzyme activator activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0000993; F:RNA polymerase II complex binding; IDA:UniProtKB.
DR   GO; GO:0003697; F:single-stranded DNA binding; IDA:UniProtKB.
DR   GO; GO:0006285; P:base-excision repair, AP site formation; IDA:UniProtKB.
DR   GO; GO:0000724; P:double-strand break repair via homologous recombination; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0006289; P:nucleotide-excision repair; IDA:UniProtKB.
DR   GO; GO:0050790; P:regulation of catalytic activity; IDA:UniProtKB.
DR   GO; GO:0009411; P:response to UV; IDA:UniProtKB.
DR   GO; GO:0010225; P:response to UV-C; IMP:UniProtKB.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; IMP:UniProtKB.
DR   CDD; cd09904; H3TH_XPG; 1.
DR   CDD; cd09868; PIN_XPG_RAD2; 2.
DR   Gene3D; 1.10.150.20; 5' to 3' exonuclease, C-terminal subdomain; 1.
DR   Gene3D; 3.40.50.1010; 5'-nuclease; 2.
DR   InterPro; IPR036279; 5-3_exonuclease_C_sf.
DR   InterPro; IPR008918; HhH2.
DR   InterPro; IPR029060; PIN-like_dom_sf.
DR   InterPro; IPR006086; XPG-I_dom.
DR   InterPro; IPR006084; XPG/Rad2.
DR   InterPro; IPR001044; XPG/Rad2_eukaryotes.
DR   InterPro; IPR019974; XPG_CS.
DR   InterPro; IPR006085; XPG_DNA_repair_N.
DR   PANTHER; PTHR16171:SF7; DNA EXCISION REPAIR PROTEIN ERCC-5; 1.
DR   PANTHER; PTHR16171; DNA REPAIR PROTEIN COMPLEMENTING XP-G CELLS-RELATED; 1.
DR   Pfam; PF00867; XPG_I; 1.
DR   Pfam; PF00752; XPG_N; 1.
DR   PRINTS; PR00853; XPGRADSUPER.
DR   PRINTS; PR00066; XRODRMPGMNTG.
DR   SMART; SM00279; HhH2; 1.
DR   SMART; SM00484; XPGI; 1.
DR   SMART; SM00485; XPGN; 1.
DR   SUPFAM; SSF47807; 5' to 3' exonuclease, C-terminal subdomain; 1.
DR   SUPFAM; SSF88723; PIN domain-like; 1.
DR   PROSITE; PS00841; XPG_1; 1.
DR   PROSITE; PS00842; XPG_2; 1.
DR   TIGRFAMs; TIGR00600; rad2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Chromosome;
KW   Cockayne syndrome; Deafness; Disease variant; DNA damage; DNA repair;
KW   DNA-binding; Dwarfism; Endonuclease; Hydrolase; Magnesium; Metal-binding;
KW   Nuclease; Nucleus; Phosphoprotein; Reference proteome;
KW   Xeroderma pigmentosum.
FT   CHAIN           1..1186
FT                   /note="DNA excision repair protein ERCC-5"
FT                   /id="PRO_0000154031"
FT   REGION          1..78
FT                   /note="N-domain"
FT                   /evidence="ECO:0000305|PubMed:32522879"
FT   REGION          31..67
FT                   /note="DNA-binding; may bind to the undamaged single-strand
FT                   DNA of the DNA repair bubble"
FT                   /evidence="ECO:0000269|PubMed:32821917,
FT                   ECO:0000312|PDB:6TUW, ECO:0007744|PDB:6TUX"
FT   REGION          79..785
FT                   /note="Spacer region"
FT                   /evidence="ECO:0000269|PubMed:16246722"
FT   REGION          306..342
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          354..385
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          404..473
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          510..533
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          667..724
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          786..881
FT                   /note="I-domain"
FT                   /evidence="ECO:0000305|PubMed:32522879"
FT   REGION          820..836
FT                   /note="DNA-binding; may bind to the undamaged single-strand
FT                   DNA of the DNA repair bubble"
FT                   /evidence="ECO:0000269|PubMed:32821917,
FT                   ECO:0000312|PDB:6TUW, ECO:0007744|PDB:6TUX"
FT   REGION          848..880
FT                   /note="DNA-binding; H2TH (helix-2turn-helix) motif which
FT                   binds double-stranded DNA"
FT                   /evidence="ECO:0000269|PubMed:32821917,
FT                   ECO:0000312|PDB:6TUW, ECO:0007744|PDB:6TUX"
FT   REGION          912..918
FT                   /note="DNA-binding; may bind double-stranded DNA"
FT                   /evidence="ECO:0000269|PubMed:32821917,
FT                   ECO:0000312|PDB:6TUW, ECO:0007744|PDB:6TUX"
FT   REGION          981..1009
FT                   /note="Interaction with PCNA"
FT                   /evidence="ECO:0000269|PubMed:9305916"
FT   REGION          1011..1186
FT                   /note="Interaction with ERCC6/CSB"
FT                   /evidence="ECO:0000269|PubMed:16246722"
FT   REGION          1056..1081
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1095..1186
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1057..1074
FT                   /note="Nuclear localization signal 1"
FT                   /evidence="ECO:0000305|PubMed:26812207"
FT   MOTIF           1169..1186
FT                   /note="Nuclear localization signal 2"
FT                   /evidence="ECO:0000305|PubMed:26812207"
FT   COMPBIAS        443..458
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        676..724
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1095..1150
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1168..1186
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         30
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   BINDING         77
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   BINDING         789
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   BINDING         791
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   BINDING         810
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   BINDING         812
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   BINDING         861
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P39748"
FT   MOD_RES         8
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         384
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P35689"
FT   MOD_RES         705
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P35689"
FT   VAR_SEQ         1..767
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_035380"
FT   VAR_SEQ         225..232
FT                   /note="ESDDFSQY -> VYLPLLQP (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053828"
FT   VAR_SEQ         233..1186
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053829"
FT   VARIANT         28
FT                   /note="A -> D (in XP-G; patient cells show a strong DNA
FT                   repair defect in response to UV light but not in response
FT                   to oxidative stress; decreased nucleotide-excision repair
FT                   activity; dbSNP:rs267607281)"
FT                   /evidence="ECO:0000269|PubMed:23255472"
FT                   /id="VAR_075773"
FT   VARIANT         72
FT                   /note="P -> H (in XP-G; combined with features of Cockayne
FT                   syndrome; dbSNP:rs121434574)"
FT                   /evidence="ECO:0000269|PubMed:11228268"
FT                   /id="VAR_015280"
FT   VARIANT         145
FT                   /note="V -> I (in dbSNP:rs4987063)"
FT                   /id="VAR_020431"
FT   VARIANT         181
FT                   /note="H -> R (in dbSNP:rs4150295)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_023120"
FT   VARIANT         254
FT                   /note="M -> V (in dbSNP:rs1047769)"
FT                   /evidence="ECO:0000269|PubMed:7510366,
FT                   ECO:0000269|PubMed:8413238, ECO:0000269|Ref.5,
FT                   ECO:0000269|Ref.6"
FT                   /id="VAR_007732"
FT   VARIANT         256
FT                   /note="Q -> R (in dbSNP:rs4150313)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_020432"
FT   VARIANT         311
FT                   /note="S -> C (in dbSNP:rs2307491)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_014829"
FT   VARIANT         399
FT                   /note="E -> K (in dbSNP:rs4150315)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_023121"
FT   VARIANT         529
FT                   /note="C -> S (in dbSNP:rs2227869)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_020433"
FT   VARIANT         590
FT                   /note="V -> I (in dbSNP:rs4150318)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_023122"
FT   VARIANT         597
FT                   /note="V -> L (in dbSNP:rs4150319)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_023123"
FT   VARIANT         670
FT                   /note="F -> L (in dbSNP:rs1803542)"
FT                   /id="VAR_046373"
FT   VARIANT         680
FT                   /note="Q -> R (in dbSNP:rs4987168)"
FT                   /id="VAR_020434"
FT   VARIANT         792
FT                   /note="A -> V (in XP-G; mild form; dbSNP:rs121434571)"
FT                   /evidence="ECO:0000269|PubMed:7951246"
FT                   /id="VAR_007733"
FT   VARIANT         858
FT                   /note="L -> P (in XP-G; reduced stability and greatly
FT                   impaired endonuclease activity; dbSNP:rs121434575)"
FT                   /evidence="ECO:0000269|PubMed:11841555"
FT                   /id="VAR_017097"
FT   VARIANT         874
FT                   /note="A -> T (in XP-G; mild form; residual activity;
FT                   dbSNP:rs121434576)"
FT                   /evidence="ECO:0000269|PubMed:12060391"
FT                   /id="VAR_017096"
FT   VARIANT         879
FT                   /note="N -> S (in dbSNP:rs4150342)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_020435"
FT   VARIANT         968
FT                   /note="W -> C (in XP-G; patient cells show a strong DNA
FT                   repair defect in response to UV light but not in response
FT                   to oxidative stress; decreased nucleotide-excision repair
FT                   activity; dbSNP:rs267607280)"
FT                   /evidence="ECO:0000269|PubMed:23255472"
FT                   /id="VAR_075774"
FT   VARIANT         1009
FT                   /note="R -> H (in dbSNP:rs4150387)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_023124"
FT   VARIANT         1053
FT                   /note="G -> R (in dbSNP:rs9514066)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7510366, ECO:0000269|PubMed:8413238,
FT                   ECO:0000269|PubMed:8483504, ECO:0000269|Ref.5,
FT                   ECO:0000269|Ref.6"
FT                   /id="VAR_046374"
FT   VARIANT         1078
FT                   /note="S -> A (found in a patient diagnosed with multiple
FT                   sclerosis; unknown pathological significance;
FT                   dbSNP:rs760347832)"
FT                   /evidence="ECO:0000269|PubMed:30533531"
FT                   /id="VAR_085644"
FT   VARIANT         1080
FT                   /note="G -> Q (requires 2 nucleotide substitutions;
FT                   dbSNP:rs587778291)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_023125"
FT   VARIANT         1080
FT                   /note="G -> R (in dbSNP:rs9514067)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7510366, ECO:0000269|PubMed:8413238,
FT                   ECO:0000269|PubMed:8483504, ECO:0000269|Ref.5,
FT                   ECO:0000269|Ref.6"
FT                   /id="VAR_046375"
FT   VARIANT         1104
FT                   /note="D -> H (in dbSNP:rs17655)"
FT                   /evidence="ECO:0000269|PubMed:8483504"
FT                   /id="VAR_007734"
FT   VARIANT         1119
FT                   /note="A -> V (in dbSNP:rs2227871)"
FT                   /id="VAR_020436"
FT   MUTAGEN         67..68
FT                   /note="FF->AA: Slight reduction in endonuclease activity.
FT                   Increased affinity for bubble DNA."
FT                   /evidence="ECO:0000269|PubMed:32522879"
FT   MUTAGEN         955..956
FT                   /note="LD->AA: Reduced protein stability, two-fold decrease
FT                   in 15-nt bubble DNA incision activity and smaller decrease
FT                   in YDNA incision activity; when associated with A-978 and
FT                   A-981."
FT                   /evidence="ECO:0000269|PubMed:32522879"
FT   MUTAGEN         978
FT                   /note="F->A: Reduced protein stability, two-fold decrease
FT                   in 15-nt bubble DNA incision activity and smaller decrease
FT                   in YDNA incision activity; when associated with 955-A-A-956
FT                   and A-981."
FT                   /evidence="ECO:0000269|PubMed:32522879"
FT   MUTAGEN         981
FT                   /note="L->A: Reduced protein stability, two-fold decrease
FT                   in 15-nt bubble DNA incision activity and smaller decrease
FT                   in YDNA incision activity; when associated with 955-A-A-956
FT                   and A-978."
FT                   /evidence="ECO:0000269|PubMed:32522879"
FT   CONFLICT        55
FT                   /note="L -> P (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        120..122
FT                   /note="KTA -> QTS (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        126
FT                   /note="K -> Q (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264..266
FT                   /note="RQY -> SSH (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        760
FT                   /note="I -> F (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        796
FT                   /note="I -> V (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        864..872
FT                   /note="EGIPTVGCV -> GNTNCGLC (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        959
FT                   /note="R -> S (in Ref. 2; BAA03812)"
FT                   /evidence="ECO:0000305"
FT   STRAND          713..715
FT                   /evidence="ECO:0007829|PDB:6TUS"
FT   HELIX           716..724
FT                   /evidence="ECO:0007829|PDB:6TUX"
FT   TURN            755..757
FT                   /evidence="ECO:0007829|PDB:6TUX"
FT   HELIX           766..779
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   STRAND          783..785
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           790..799
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   STRAND          802..804
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           812..815
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   STRAND          820..823
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   STRAND          830..836
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           837..844
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           848..858
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           871..880
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           887..901
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           913..919
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           930..937
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           955..966
FT                   /evidence="ECO:0007829|PDB:6VBH"
FT   HELIX           970..985
FT                   /evidence="ECO:0007829|PDB:6VBH"
SQ   SEQUENCE   1186 AA;  133108 MW;  B0A844D617C53F2E CRC64;
     MGVQGLWKLL ECSGRQVSPE ALEGKILAVD ISIWLNQALK GVRDRHGNSI ENPHLLTLFH
     RLCKLLFFRI RPIFVFDGDA PLLKKQTLVK RRQRKDLASS DSRKTTEKLL KTFLKRQAIK
     TAFRSKRDEA LPSLTQVRRE NDLYVLPPLQ EEEKHSSEEE DEKEWQERMN QKQALQEEFF
     HNPQAIDIES EDFSSLPPEV KHEILTDMKE FTKRRRTLFE AMPEESDDFS QYQLKGLLKK
     NYLNQHIEHV QKEMNQQHSG HIRRQYEDEG GFLKEVESRR VVSEDTSHYI LIKGIQAKTV
     AEVDSESLPS SSKMHGMSFD VKSSPCEKLK TEKEPDATPP SPRTLLAMQA ALLGSSSEEE
     LESENRRQAR GRNAPAAVDE GSISPRTLSA IKRALDDDED VKVCAGDDVQ TGGPGAEEMR
     INSSTENSDE GLKVRDGKGI PFTATLASSS VNSAEEHVAS TNEGREPTDS VPKEQMSLVH
     VGTEAFPISD ESMIKDRKDR LPLESAVVRH SDAPGLPNGR ELTPASPTCT NSVSKNETHA
     EVLEQQNELC PYESKFDSSL LSSDDETKCK PNSASEVIGP VSLQETSSIV SVPSEAVDNV
     ENVVSFNAKE HENFLETIQE QQTTESAGQD LISIPKAVEP MEIDSEESES DGSFIEVQSV
     ISDEELQAEF PETSKPPSEQ GEEELVGTRE GEAPAESESL LRDNSERDDV DGEPQEAEKD
     AEDSLHEWQD INLEELETLE SNLLAQQNSL KAQKQQQERI AATVTGQMFL ESQELLRLFG
     IPYIQAPMEA EAQCAILDLT DQTSGTITDD SDIWLFGARH VYRNFFNKNK FVEYYQYVDF
     HNQLGLDRNK LINLAYLLGS DYTEGIPTVG CVTAMEILNE FPGHGLEPLL KFSEWWHEAQ
     KNPKIRPNPH DTKVKKKLRT LQLTPGFPNP AVAEAYLKPV VDDSKGSFLW GKPDLDKIRE
     FCQRYFGWNR TKTDESLFPV LKQLDAQQTQ LRIDSFFRLA QQEKEDAKRI KSQRLNRAVT
     CMLRKEKEAA ASEIEAVSVA MEKEFELLDK AKGKTQKRGI TNTLEESSSL KRKRLSDSKG
     KNTCGGFLGE TCLSESSDGS SSEDAESSSL MNVQRRTAAK EPKTSASDSQ NSVKEAPVKN
     GGATTSSSSD SDDDGGKEKM VLVTARSVFG KKRRKLRRAR GRKRKT
//
